These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 27706103)

  • 1. In Vitro Metabolic Studies of REV-ERB Agonists SR9009 and SR9011.
    Geldof L; Deventer K; Roels K; Tudela E; Van Eeno P
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27706103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological activation of the nuclear receptor REV-ERB reverses cognitive deficits and reduces amyloid-β burden in a mouse model of Alzheimer's disease.
    Roby DA; Ruiz F; Kermath BA; Voorhees JR; Niehoff M; Zhang J; Morley JE; Musiek ES; Farr SA; Burris TP
    PLoS One; 2019; 14(4):e0215004. PubMed ID: 30973894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid investigating of phase I metabolites of SR9009 in vitro horse liver microsomes via feature-based molecular networking approach: Potential applications in doping control.
    Kwak YB; Yoon J; Yoo HH
    J Pharm Biomed Anal; 2024 Aug; 246():116190. PubMed ID: 38735208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of exercise ability and glycolipid metabolism by synthetic SR9009 analogues as new REV-ERB-α agonists.
    Li L; Yang C; Qiao X; Yang X; Zhang J; Cui M; Li Z; Tian A; Li X; Zou X; Li Y; He W; Chen Y; He X
    Bioorg Med Chem; 2024 Sep; 111():117845. PubMed ID: 39059249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence.
    Sulli G; Rommel A; Wang X; Kolar MJ; Puca F; Saghatelian A; Plikus MV; Verma IM; Panda S
    Nature; 2018 Jan; 553(7688):351-355. PubMed ID: 29320480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rev-erb regulation of cholesterologenesis.
    Sitaula S; Zhang J; Ruiz F; Burris TP
    Biochem Pharmacol; 2017 May; 131():68-77. PubMed ID: 28213272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disrupting the key circadian regulator CLOCK leads to age-dependent cardiovascular disease.
    Alibhai FJ; LaMarre J; Reitz CJ; Tsimakouridze EV; Kroetsch JT; Bolz SS; Shulman A; Steinberg S; Burris TP; Oudit GY; Martino TA
    J Mol Cell Cardiol; 2017 Apr; 105():24-37. PubMed ID: 28223222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rev-erb agonist and TGF-β similarly affect autophagy but differentially regulate hepatic stellate cell fibrogenic phenotype.
    Thomes PG; Brandon-Warner E; Li T; Donohue TM; Schrum LW
    Int J Biochem Cell Biol; 2016 Dec; 81(Pt A):137-147. PubMed ID: 27840152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action.
    Yu Z; He S; Wang D; Patel HK; Miller CP; Brown JL; Hattersley G; Saeh JC
    Clin Cancer Res; 2017 Dec; 23(24):7608-7620. PubMed ID: 28974548
    [No Abstract]   [Full Text] [Related]  

  • 10. REV-ERBα ameliorates heart failure through transcription repression.
    Zhang L; Zhang R; Tien CL; Chan RE; Sugi K; Fu C; Griffin AC; Shen Y; Burris TP; Liao X; Jain MK
    JCI Insight; 2017 Sep; 2(17):. PubMed ID: 28878135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. REV-ERB and ROR: therapeutic targets for treating myopathies.
    Welch RD; Flaveny CA
    Phys Biol; 2017 Jun; 14(4):045002. PubMed ID: 28586319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rev-erb agonist improves adverse cardiac remodeling and survival in myocardial infarction through an anti-inflammatory mechanism.
    Stujanna EN; Murakoshi N; Tajiri K; Xu D; Kimura T; Qin R; Feng D; Yonebayashi S; Ogura Y; Yamagami F; Sato A; Nogami A; Aonuma K
    PLoS One; 2017; 12(12):e0189330. PubMed ID: 29232411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SR9009 has REV-ERB-independent effects on cell proliferation and metabolism.
    Dierickx P; Emmett MJ; Jiang C; Uehara K; Liu M; Adlanmerini M; Lazar MA
    Proc Natl Acad Sci U S A; 2019 Jun; 116(25):12147-12152. PubMed ID: 31127047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A further insight into the metabolic profile of the nuclear receptor Rev-erb agonist, SR9009.
    Mazzarino M; Rizzato N; Stacchini C; de la Torre X; Botrè F
    Drug Test Anal; 2018 Nov; 10(11-12):1670-1681. PubMed ID: 30395700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapeutic Effect of SR9009, a REV-ERB Agonist, on the Human Glioblastoma T98G Cells.
    Wagner PM; Monjes NM; Guido ME
    ASN Neuro; 2019; 11():1759091419892713. PubMed ID: 31825658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. REV-ERBβ is required to maintain normal wakefulness and the wake-inducing effect of dual REV-ERB agonist SR9009.
    Amador A; Kamenecka TM; Solt LA; Burris TP
    Biochem Pharmacol; 2018 Apr; 150():1-8. PubMed ID: 29355503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock.
    Ishimaru K; Nakajima S; Yu G; Nakamura Y; Nakao A
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31847374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melatonin modulates dysregulated circadian clocks in mice with diethylnitrosamine-induced hepatocellular carcinoma.
    Sánchez DI; González-Fernández B; Crespo I; San-Miguel B; Álvarez M; González-Gallego J; Tuñón MJ
    J Pineal Res; 2018 Oct; 65(3):e12506. PubMed ID: 29770483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SR9009 administered for one day after myocardial ischemia-reperfusion prevents heart failure in mice by targeting the cardiac inflammasome.
    Reitz CJ; Alibhai FJ; Khatua TN; Rasouli M; Bridle BW; Burris TP; Martino TA
    Commun Biol; 2019; 2():353. PubMed ID: 31602405
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.